Skip to main content
Year archive

Nanobiotix — 2023 filings

All 71 regulatory filings released by Nanobiotix (NANO) in 2023, sourced directly from the official regulator.

71 Filings
2023 Period
2023 filings (71)
Filing Released Lang
Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets
M&A Activity
2023-12-26 English
LianBio Transfere Ses Droits De Développement Et De Commercialisation De NBTXR3 En Chine Et Dans D’autres Marchés Asiatiques
M&A Activity
2023-12-26 French
Voting Rights and Shares Capital of the Company
Declaration of Voting Results & Voting Rights Announcements
2023-12-13 English
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Declaration of Voting Results & Voting Rights Announcements
2023-12-13 French
NANOBIOTIX ANNONCE LA CLÔTURE DE L'INVESTISSEMENT RESTANT DE 4,8 MILLIONS DE DOLLARS DE JOHNSON & JOHNSON INNOVATION - JJDC, INC.
Share Issue/Capital Change
2023-12-04 French
Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.
Share Issue/Capital Change
2023-12-04 English
Franchissement de seuil et déclaration d'intention
Major Shareholding Notification
2023-11-30 French
NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update
Earnings Release Q3 2023
2023-11-13 English
NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers pour le troisième trimestre 2023
Earnings Release Q3 2023
2023-11-13 French
Franchissement de seuils et déclaration d'intention
Major Shareholding Notification
2023-11-10 French
NANOBIOTIX annoncera ses résultats financiers du troisième trimestre 2023, le 13 novembre 2023
Report Publication Announcement
2023-11-09 French
NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023
Report Publication Announcement
2023-11-09 English
Franchissement de seuils
Major Shareholding Notification
2023-11-09 French
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Declaration of Voting Results & Voting Rights Announcements
2023-11-08 French
Voting Rights and Shares Capital of the Company
Declaration of Voting Results & Voting Rights Announcements
2023-11-08 English
NANOBIOTIX annonce le reglement-livraison de son offre globale
Capital/Financing Update
2023-11-07 French
NANOBIOTIX Announces Closing of Global Offering
Share Issue/Capital Change
2023-11-07 English
NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment
Capital/Financing Update
2023-11-06 English
NANOBIOTIX annonce le lancement d’une offre globale et d’un placement prive concomitant ainsi que la renonciation par la BEI de l’engagement de tresorerie minimum dont elle beneficie
Capital/Financing Update
2023-11-01 French
NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant
Capital/Financing Update
2023-11-01 English
NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023
Earnings Release FY 2023
2023-10-23 English
ESMO 2023 : NANOBIOTIX annonce une mise a jour des résultats préliminaires d’une étude de phase 1 dans le cancer du pancréas et une nouvelle analyse exploratoire de l’étude 102 dans les cancers de la
Earnings Release FY 2023
2023-10-23 French
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Declaration of Voting Results & Voting Rights Announcements
2023-10-11 French
Voting Rights and Shares Capital of the Company
Declaration of Voting Results & Voting Rights Announcements
2023-10-11 English
NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation O
Earnings Release FY 2023
2023-09-29 English
NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer
Earnings Release FY 2023
2023-09-28 English
NANOBIOTIX annonce la présentation des premières données de l’étude de phase 1 évaluant NBTXR3 chez des patients atteints d’un cancer du pancréas localement avancé
Regulatory Filings
2023-09-28 French
RFS Nanobiotix Juin 2023
Interim / Quarterly Report H2 2023
2023-09-26 French
NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers pour le premier semestre 2023
Earnings Release H1 2023
2023-09-26 French
NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023
Earnings Release H2 2023
2023-09-26 English
Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023
Report Publication Announcement
2023-09-19 English
Nanobiotix annoncera ses résultats financiers du premier semestre 2023, le 26 septembre 2023
Report Publication Announcement
2023-09-19 French
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Share Issue/Capital Change
2023-09-13 French
Voting Rights and Shares Capital of the Company
Share Issue/Capital Change
2023-09-13 English
Franchissement de seuil
Major Shareholding Notification
2023-09-13 French
Franchissement de seuil
Major Shareholding Notification
2023-09-07 French
NANOBIOTIX renforce ses capacités de développement international avec la nomination d’un leader experimenté de l’industrie, le Dr. Louis Kayitalire, au poste de Chief medical officer
Board/Management Information
2023-09-05 French
NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer
Board/Management Information
2023-09-05 English
NANOBIOTIX participera à la 25ème édition de la conférence internationale investisseurs H.C. Wainwright
Regulatory Filings
2023-08-31 French
NANOBIOTIX to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Regulatory Filings
2023-08-31 English
NANOBIOTIX annonce l’entree en vigeur de l’accord de licence globale pour le co-développement et la commercialisation de NBTXR3, son potentiel radioenhancer first-in-class
Earnings Release FY 2023
2023-08-15 French
NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3
Regulatory Filings
2023-08-15 English
NANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023
AGM Information
2023-08-04 English
NANOBIOTIX annonce une assemblée générale extraordinaire qui se tiendra le 1er septembre 2023
AGM Information
2023-08-04 French
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements
2023-07-20 French
Voting Rights and Shares Capital of the Company
Declaration of Voting Results & Voting Rights Announcements
2023-07-20 English
NANOBIOTIX annonce qu’un premier patient a reçu une injection de NBTXR3 dans le cadre d’une nouvelle étude de Phase 1/2 évaluant NBTXR3 activé par radiothérapie et associé à un anti-PD-1 chez des pati
Regulatory Filings
2023-07-19 French
NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers
Regulatory Filings
2023-07-19 English
NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3
Earnings Release FY 2023
2023-07-10 English
NANOBIOTIX annonce la signature d’un accord de licence globale pour le co-développement et la commercialisation de NBTXR3, son potentiel radioenhancer first-in-class
Earnings Release FY 2023
2023-07-10 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements
2023-06-08 French
Voting Rights and Shares Capital of the Company
Declaration of Voting Results & Voting Rights Announcements
2023-06-08 English
NANOBIOTIX FAIT LE POINT SUR SES ACTIVITÉS ET PUBLIE SES RÉSULTATS FINANCIERS POUR LE PREMIER TRIMESTRE 2023
Earnings Release Q1 2023
2023-05-17 French
NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update
Earnings Release Q1 2023
2023-05-17 English
NANOBIOTIX entre en négociation contractuelle finale à la suite de l’accord sur un non-binding term sheet pour le developpement et la commercialisation de NBTXR3 avec un leader mondial de l’industrie
Regulatory Filings
2023-05-05 French
NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company
Regulatory Filings
2023-05-05 English
NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers pour l’année 2022
Earnings Release FY 2022
2023-04-25 French
NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results
Earnings Release FY 2022
2023-04-25 English
Nanobiotix - AMF - URD 2022 - december 2022
Annual Report (ESEF) FY 2022
2023-04-24 English
Nanobiotix - AMF - URD 2022 - december 2022
Annual Report (ESEF) FY 2022
2023-04-24 English
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Declaration of Voting Results & Voting Rights Announcements
2023-04-11 French
Voting Rights and Shares Capital of the Company
Share Issue/Capital Change
2023-04-11 English
Nanobiotix reporte la publication de ses résultats financiers de l'exercice 2022 et la confé?rence téléphonique
Report Publication Announcement
2023-03-27 French
Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call
Report Publication Announcement
2023-03-27 English
Nanobiotix publiera le 28 mars 2023 ses résultats financiers de l'exercice 2022 et fera le point sur ses activités opérationnelles
Report Publication Announcement
2023-03-14 French
Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023
Report Publication Announcement
2023-03-14 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Share Issue/Capital Change
2023-02-14 French
Voting Rights and Shares Capital of the Company
Share Issue/Capital Change
2023-02-14 English
Voting Rights and Shares Capital of the Company
Share Issue/Capital Change
2023-01-11 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Share Issue/Capital Change
2023-01-11 French
Franchissement de seuil
Major Shareholding Notification
2023-01-09 French